Market Size and Forecast
The women health therapeutics market is growing rapidly due to increasing awareness among patients & physicians and introduction of new therapies in the market. The women health therapeutics market was USD 14,530 million in 2010 and is expected to reach at USD 24,669 million by 2017 at an estimated CAGR of 7.9% during 2010-2017.
The menopause therapeutics market segment and post menopause osteoporosis market segment are expected to have maximum potential in women health therapeutics market during the forecast period.
Currently the menopause therapeutics market is driven by hormone therapeutics, which is less health concerned. New entrance of Non-hormones therapeutics is expected to compete with the currently marketed drugs and will significantly change the market dynamics.
The current women health therapeutics market has strong pipe-line of first-in-class molecules in clinical development such as Pristiq, Aprela, Menerba, Elagolix and Cetrorelix. Apart from this, porlia a first-in-class drug newly introduced by Amgen Inc. it is expected to drive the post menopausal osteoporosis therapeutics market in term of volume and expected to generate revenue of USD 1 billion annually during forecasted period. Novel, non-hormonal therapeutics is expected to become more popular during the forecasted period for treatment of menopause therapeutics market. Thus there are huge opportunities for new non hormone therapeutics drugs in women health therapeutics market.
The women health therapeutics market is consolidated as top five players in the market accounts for more than 80% of the total women health therapeutics market. Eli Lilly is the current market leader by accounting for approximately 26% of the total women health therapeutics market. Eli Lilly leadership is driven by two major selling drugs, Evista and Forteo for the treatment of post menopause osteoporosis. Merck accounts for 16% share of women health therapeutics market while Pfizer holds 15% share of women health therapeutics market.